SLC5A2 and heart failure: A total of three cohort studies [13–15] reported the risk of heart failure exacerbation was lower in those who received SGLT2 inhibitors, though the results were not statistically significant, with a pooled RR of 0.67 (95% CI 0.39–1.14, I2 17%).